When ICI were used to interfere with PD-1 and PD-L1, which was expressed on the majority of tumor cells, there was no improvement in anti-tumor response observed, even when these ICI where combined with anti-CTLA-4. The gene discussed is PDCD1; the disease is neoplasm.